scholarly journals IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal

2012 ◽  
Vol 6 (3) ◽  
pp. 784-789 ◽  
Author(s):  
Kazuya Okushin ◽  
Yoshinari Asaoka ◽  
Izumi Fukuda ◽  
Naoto Fujiwara ◽  
Tatsuya Minami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Molecular Targeting ◽  
Metabolic Complications ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma

2017 ◽  
Vol 35 (6) ◽  
pp. 618-622 ◽  
Author(s):  
Naoshi Nishida ◽  
Masatoshi Kudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Molecular Targeting ◽  
Advanced Hepatocellular Carcinoma ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents. On the contrary, immune checkpoint inhibitors have proven effective in patients who are refractory to conventional treatments and molecular targeting therapy. Several clinical trials are currently investigating the efficacy of immune checkpoint inhibitors both individually and in combination with other types of anticancer agents. In this review, we focus on the potential of immune checkpoint blockade in the treatment of human HCC.

Molecular targeting therapy: Cancer stem cell and invasion/metastasis

Toukeibu Gan ◽  
2010 ◽  
Vol 36 (4) ◽  
pp. 442-446
Author(s):  
Ichiro Ota ◽  
Noritomo Okamoto ◽  
Katsunari Yane ◽  
Hiroshi Hosoi
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Molecular Targeting ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors

2011 ◽  
Vol 11 (9) ◽  
pp. 1082-1097 ◽  
Author(s):  
RONG Biao-xue ◽  
CAI Xi-guang ◽  
YANG Shuan-ying ◽  
LI Wei ◽  
MING Zong-juan
Keyword(s):  
Malignant Tumors ◽  
Molecular Targeting ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

scholarly journals Molecular Targeting Therapy for Fukuyama Muscular Dystrophy

2012 ◽  
Vol 52 (11) ◽  
pp. 1158-1158
Author(s):  
Tatsushi Toda ◽  
Mariko Taniguchi-Ikeda ◽  
Kazuhiro Kobayashi
Keyword(s):  
Muscular Dystrophy ◽  
Molecular Targeting ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

scholarly journals Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy

2010 ◽  
Vol 1 (4) ◽  
pp. 697-701 ◽  
Author(s):  
TAKASHI SEO ◽  
RYUICHIRO KONDA ◽  
JUN SUGIMURA ◽  
KAZUHIRO IWASAKI ◽  
YUSUKE NAKAMURA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Targeting ◽  
Promising Candidate ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy ◽  
Inducible Protein
Sign in / Sign up

Export Citation Format

Share Document